Taysha Gene Therapies Inc (TSHA) FinancialsTSHATaysha Gene Therapies Inc

Evaluating the bottom line, Taysha Gene Therapies, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -47.05%, provide a clear picture of how effectively TSHA converts its operational activities into shareholder value.

In the context of the broader market, TSHA competes directly with industry leaders such as IMCR and KARD. With a market capitalization of $1.94B, it holds a leading position in the sector. When comparing efficiency, TSHA's gross margin of N/A stands against IMCR's 99.06% and KARD's N/A. Such benchmarking helps identify whether Taysha Gene Therapies, Inc. is trading at a premium or discount relative to its financial performance.

Taysha has shown a gross margin of 100% in recent quarters, indicating strong revenue potential despite losses. However, it reported a net loss of $46.6 million in Q2 2026, which raises concerns about profitability.